Tecan Group AG (TECN) AI Stock Analysis

• Market Cap: CHF1.47B
• Dividend Yield: 2.31%
• Average Volume (3M): 44.12K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.12
• Revenue Growth: -9.34%
• EPS Growth: -37.50%
• Country: CH
• Employees: 3,074
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 4.26
• Shares Outstanding: 12,825,883
• 10 Day Avg. Volume: 56,389
• 30 Day Avg. Volume: 44,118
• PEG Ratio: 0.06
• Price to Book (P/B): 1.41
• Price to Sales (P/S): 1.84
• P/FCF Ratio: 15.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF162.00
• Price Target Upside: 41.24% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 5
• EPS Forecast (FY): 6.03
• Revenue Forecast (FY): CHF882.47M

• Rating: 55 Neutral
• Price Target: CHF119.00 ▲(3.75% Upside)
• Action: Reiterated Date: 03/23/26
• Date: Action: Reiterated 03/23/26

The score is held back mainly by deteriorating financial performance (continued revenue declines, major margin compression, and a 2025 net loss). Technicals also look weak with the stock below key moving averages and negative MACD. Offsetting this, the balance sheet remains conservative with positive cash flow, and the latest call maintained guidance with strong order entry and a share buyback, but external headwinds (China, Partnering softness, tariffs/currency) keep risk elevated.

Positive Factors

Conservative balance sheet and low leverage

Sustained low leverage gives Tecan financial flexibility to fund R&D, service the installed base, and execute the CHF 120m buyback without stressing liquidity. This conservatism supports resilience through cyclical revenue pressure and underpins multi‑year strategic investments and partnerships.

Recurring revenue from installed base and OEMs

A large installed base plus consumables, service contracts, software and OEM supply create recurring revenue and higher lifetime customer value. This mix smooths cash flows, supports margin durability, and provides a platform for cross‑sell and long‑term customer lock‑in in diagnostics and biopharma markets.

Positive operating cash generation despite pressures

Consistent positive operating cash flow even during a loss year indicates strong cash conversion from core activities. That cash generation funds capex, supports service operations and product launches, and gives management room to invest or return capital while addressing margin headwinds.

Negative Factors

Three years of revenue decline and margin compression

Sustained top‑line declines and a structural fall in operating margin reduce scale economics and weaken the firm's ability to fund R&D and service investments. If persistent, this erodes competitive positioning, compresses reinvestment capacity, and increases sensitivity to external shocks over the medium term.

Partnering business weakness and China headwinds

Declines in the Partnering segment and weak China demand hit a strategic revenue channel and OEM pipeline. Prolonged softness in these areas limits diversified growth, reduces predictable multi‑year OEM revenues, and raises execution risk for product rollouts tied to those markets.

Weakened free cash flow and earnings quality in 2025

A sharp drop in free cash flow and shrinking equity in 2025 signal deteriorating earnings quality and capital erosion. This reduces internal funding for innovation and cushion against shocks, making the company more reliant on operational recovery or external financing to restore long‑term growth.

Tecan Group AG Business Overview & Revenue Model

Company Description

Tecan Group AG provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. It operates through Life Sciences Business and Partnering Business segments. The company offers liquid handling and automation, microplate readers and washers, consumables, NGS reagents, immunoassays and microbodies, and software; Tecan Laberwax, an automation solution; Resolvex, a smart sample preparation solution for use in genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA solutions. It also develops and manufactures laboratory instrument manufacturers with essential components comprising precision pumps, valves, robotic arms, and developer software for life science research, diagnostics, and various other industries; Synergence, platform-based automation solution; and Freedom EVO and Fluent instruments. The company operates in Switzerland and Other European countries, North America, Asia, and internationally. Tecan Group AG was founded in 1980 and is headquartered in Männedorf, Switzerland.

How the Company Makes Money

Tecan makes money primarily by selling laboratory automation instruments and related solutions, and by generating recurring revenue from the ongoing use and support of those systems. A major revenue stream comes from instrument sales (e.g., automated liquid handling/workstation platforms and integration modules) to laboratories and to other companies that incorporate Tecan technology. The company also earns recurring revenue from consumables (such as disposable tips and other lab plastics used with its instruments), which are replenished regularly as customers run assays and workflows. Additional revenue is generated from software licenses and upgrades that operate and manage automated workflows, as well as from service and support activities including installation, maintenance contracts, repairs, validation, and application support. Another important part of the model is its OEM business, where Tecan supplies automation platforms, components, and/or subsystems to instrument makers and in vitro diagnostics companies that sell finished systems under their own brands; these relationships can drive multi-year product supply revenues alongside engineering/customization work. Factors contributing to earnings include the installed base of instruments (which supports repeat consumables and service revenue), long-term OEM supply relationships, and demand from regulated clinical/IVD and biopharma markets that value automated, high-throughput, and standardized laboratory workflows.

Tecan Group AG Financial Statement Overview

Summary

Income statement is weak (Score 42) with three straight years of revenue decline, sharp operating margin compression (~4.8% in 2025 vs ~12–16% earlier), and a swing to a large net loss in 2025. Offsetting factors are a sturdy balance sheet (Score 74, low debt-to-equity ~0.19–0.26) and still-positive cash generation (Cash Flow Score 67), though free cash flow fell meaningfully in 2025.

Income Statement

Revenue has declined for three straight years (2023: -6.1%, 2024: -0.1%, 2025: -2.7%), and profitability has compressed materially versus 2020–2022. Gross margin has been relatively steady in the mid-30% range recently, but operating margin fell to ~4.8% in 2025 from ~12–16% in 2020–2023. The biggest issue is the swing to a large net loss in 2025 (net margin about -12.5%) after solid profitability in 2021–2024, indicating elevated non-operating or one-time pressure and weaker earnings quality in the most recent year.

Balance Sheet

Leverage appears conservative: debt-to-equity remains low (~0.19–0.26 across 2021–2025), providing balance-sheet flexibility. However, equity and total assets stepped down in 2025 versus 2024, consistent with the net loss impacting capital, and return on equity weakened sharply (positive mid-to-high single digits in 2022–2024, then effectively nil in 2025). Overall, the balance sheet looks sturdy, but the recent earnings drawdown is a key watch item.

Cash Flow

Cash generation remains a relative strength: operating cash flow stayed positive in every year shown, including 2025, and free cash flow remained solid. That said, free cash flow declined meaningfully in 2025 (about -31.6% growth), signaling softer underlying cash momentum. Cash conversion versus earnings looks supportive in most years (free cash flow tracked below net income during profitable periods), but 2025’s net loss makes earnings-based comparisons less informative; the main takeaway is that cash flow held up better than reported earnings, though it weakened year over year.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	882.48M	934.28M	1.07B	1.14B	946.62M
Gross Profit	310.84M	320.60M	390.47M	405.32M	388.02M
EBITDA	42.17M	147.80M	205.57M	210.85M	201.22M
Net Income	-110.65M	67.66M	132.07M	121.13M	121.66M
Balance Sheet
Total Assets	1.70B	2.12B	2.07B	2.16B	2.04B
Cash, Cash Equivalents and Short-Term Investments	311.37M	406.01M	366.42M	293.24M	241.91M
Total Debt	218.32M	321.35M	316.09M	307.68M	313.66M
Total Liabilities	546.60M	686.15M	725.06M	776.40M	800.26M
Stockholders Equity	1.15B	1.44B	1.35B	1.36B	1.22B
Cash Flow
Free Cash Flow	102.67M	117.86M	125.63M	91.24M	126.12M
Operating Cash Flow	137.98M	148.54M	160.57M	127.47M	165.84M
Investing Cash Flow	76.50M	-48.61M	-84.23M	-88.22M	-651.95M
Financing Cash Flow	-187.48M	-81.30M	-50.57M	-47.82M	458.53M

Tecan Group AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 114.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:TECN, the sentiment is Negative. The current price of 114.7 is below the 20-day moving average (MA) of 126.12, below the 50-day MA of 133.29, and below the 200-day MA of 147.05, indicating a bearish trend. The MACD of -4.60 indicates Positive momentum. The RSI at 30.55 is Neutral, neither overbought nor oversold. The STOCH value of 24.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:TECN.

Tecan Group AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
YPSN	70 Outperform	CHF3.91B	7.66	27.15%	0.67%	27.63%	160.67%
MOVE	69 Neutral	CHF2.96B	34.95	23.76%	0.45%	16.59%	65.76%
SFZN	62 Neutral	CHF3.25B	19.36	15.79%	0.51%	0.77%	16.70%
TECN	55 Neutral	CHF1.47B	-14.70	4.57%	2.31%	-9.34%	-37.50%
SKAN	55 Neutral	CHF985.90M	-45.23	―	0.77%	-3.45%	-49.82%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MED	51 Neutral	CHF1.13B	-168.33	―	―	7.29%	-112.70%